Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2020 | Key multiple myeloma data from ASCO 2020

Shaji Kumar • 1 Jun 2020
ASCO 2020
Multiple Myeloma Antibodies Belantamab mafodotin Bortezomib CAR-T Carfilzomib Daratumumab Dexamethasone Selinexor
CARTITUDE-1 KarMMa

Shaji Kumar, MD, Mayo Clinic, Rochester, MN, outlines the multiple myeloma updates presented at ASCO 2020. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Shaji Kumar

Long-term efficacy and safety of etentamig, a BCMA bispecific antibody, in R/R multiple myeloma
3:00
Long-term efficacy and safety of etentamig, a BCMA bispecific antibody, in R/R multiple myeloma
Shaji Kumar • 17 Jun 2025
Long-term outcomes from the ENDURANCE trial: VRd versus KRD in newly diagnosed myeloma
2:37
Long-term outcomes from the ENDURANCE trial: VRd versus KRD in newly diagnosed myeloma
Shaji Kumar • 17 Jun 2025
The feasibility of outpatient strategies for treating multiple myeloma with bispecifics and CAR-T
1:57
The feasibility of outpatient strategies for treating multiple myeloma with bispecifics and CAR-T
Shaji Kumar • 17 Jun 2025
RedirecTT-1: the safety and efficacy of talquetamab and teclistamab in R/R multiple myeloma with EMD
5:43
RedirecTT-1: the safety and efficacy of talquetamab and teclistamab in R/R multiple myeloma with EMD
Shaji Kumar • 17 Jun 2025

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Shaji Kumar • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Shaji Kumar • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Shaji Kumar • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Shaji Kumar • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals